α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients. | Zendy

Gabriel Étienne | Zendy; Maryse Dupouy | Zendy; Patricia Costaglioli | Zendy; Claudine Chollet | Zendy; Valérie Lagarde | Zendy; JeanMax Pasquet | Zendy; Josy Reiffers | Zendy; Bertrand Garbay | Zendy; FrançoisXavier Mahon | Zendy; Béatrice Turcq | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients.

Author(s) -

Gabriel Étienne,

Maryse Dupouy,

Patricia Costaglioli,

Claudine Chollet,

Valérie Lagarde,

JeanMax Pasquet,

Josy Reiffers,

Bertrand Garbay,

FrançoisXavier Mahon,

Béatrice Turcq

Publication year - 2011

Publication title -

hal (le centre pour la communication scientifique directe)

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.912

H-Index - 66

ISSN - 1875-8630

DOI - 10.3233/dma-2011-0777

Subject(s) - imatinib , defensin , imatinib mesylate , medicine , tyrosine kinase , tyrosine kinase inhibitor , immunology , biology , myeloid leukemia , gene , genetics , receptor , cancer

Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukaemia. Despite a remarkable effectiveness, treatment failure cases have been reported in 20 percent of CML patients. The identification of biomarkers which can predict the response to imatinib is our point of interest.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research